1. Pink Sheet

PDUFA VIII: Continuous Fee Increases May Be Wearing On Sponsors

 
• By Derrick Gingery

A Pfizer exec says that the old prescription drug user fee formulas that usually increase funding and staffing for many FDA programs no longer deliver the same return on investment.

Rolling money uphill
The traditional idea of fixing FDA problems with more staff may be losing efficacy, Emmett said. • Source: Shutterstock

SAN DIEGO – Industry may no longer be willing to accept user fee increases and more hiring as the key to US Food and Drug Administration improvements, a potential change of strategy for handling the prescription drug user fee program.

Key Takeaways

  • Emmett said increasing spending and employees may not continue to fix FDA problems.

  • He suggested traditional metrics like acting on 90% of applications by...

Negotiations likely will begin in about a year on potential updates to the PDUFA program and an agreement to extend it another five years. The current program will expire after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from DIA

More from Pink Sheet

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.